Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lene Holmvang

Showing results (1-10 of 251) with videos related to

Pageof 26
Sort By:
Therapeutic Advances in Cardiovascular Disease|January 7, 2009
Gender differences following percutaneous coronary interventionLene Holmvang, Hans Mickley
Ugeskrift for Laeger|December 14, 2006
[The patient with cardiac disease]Jørn Wetterslev, Lene Holmvang
Ugeskrift for Laeger|June 28, 2007
[The effect of percutaneous coronary intervention in women with ischaemic heart disease]Lene Holmvang, Hans Mickley
Cardiovascular Drugs and Therapy|February 6, 2013
Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiologyPeter Clemmensen, Nadia Paarup Dridi, Lene Holmvang
Journal of the American College of Cardiology|May 20, 2026
Left Ventricular Unloading in STEMI: From Bench to Bedside and Back AgainJacob Eifer Møller, Lene Holmvang, Robert Yeh, et al.
Current Opinion in Critical Care|April 30, 2021
Interventional treatment of acute myocardial infarction-related cardiogenic shockJakob Josiassen, Jacob E Møller, Lene Holmvang, et al.
Prostaglandins & Other Lipid Mediators|September 7, 2012
A single center, open, randomized study investigating the clinical safety and the endothelial modulating effects of a prostacyclin analog in combination with eptifibatide in patients having undergone primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarctionLene Holmvang, Sisse Rye Ostrowski, Nadia Paarup Dridi, et al.
Platelets|May 1, 2015
Traditional clinical risk factors predict clopidogrel hypo-responsiveness in unselected patients undergoing non-emergent percutaneous coronary interventionHanna Ratcovich, Lene Holmvang, Pär Inge Johansson, et al.
Danish Medical Journal|October 2, 2018
Posture changes platelet inhibition time after ingestion of prasugrelJacob Antonsen, Nina Bundgaard, Lene Holmvang, et al.
JACC. Cardiovascular Interventions|May 26, 2026
REPLY: Bleeding in Infarct-Related Cardiogenic Shock: The Need for an Integrated Hemocompatibility AssessmentRikke Sørensen, Rasmus P Beske, Jacob E Møller, et al.
Pageof 26

Showing results (1-10 of 251) with videos related to

Sort By:
Pageof 26
Therapeutic Advances in Cardiovascular Disease|January 7, 2009
Gender differences following percutaneous coronary interventionLene Holmvang, Hans Mickley
Ugeskrift for Laeger|December 14, 2006
[The patient with cardiac disease]Jørn Wetterslev, Lene Holmvang
Ugeskrift for Laeger|June 28, 2007
[The effect of percutaneous coronary intervention in women with ischaemic heart disease]Lene Holmvang, Hans Mickley
Cardiovascular Drugs and Therapy|February 6, 2013
Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiologyPeter Clemmensen, Nadia Paarup Dridi, Lene Holmvang
Journal of the American College of Cardiology|May 20, 2026
Left Ventricular Unloading in STEMI: From Bench to Bedside and Back AgainJacob Eifer Møller, Lene Holmvang, Robert Yeh, et al.
Current Opinion in Critical Care|April 30, 2021
Interventional treatment of acute myocardial infarction-related cardiogenic shockJakob Josiassen, Jacob E Møller, Lene Holmvang, et al.
Prostaglandins & Other Lipid Mediators|September 7, 2012
A single center, open, randomized study investigating the clinical safety and the endothelial modulating effects of a prostacyclin analog in combination with eptifibatide in patients having undergone primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarctionLene Holmvang, Sisse Rye Ostrowski, Nadia Paarup Dridi, et al.
Platelets|May 1, 2015
Traditional clinical risk factors predict clopidogrel hypo-responsiveness in unselected patients undergoing non-emergent percutaneous coronary interventionHanna Ratcovich, Lene Holmvang, Pär Inge Johansson, et al.
Danish Medical Journal|October 2, 2018
Posture changes platelet inhibition time after ingestion of prasugrelJacob Antonsen, Nina Bundgaard, Lene Holmvang, et al.
JACC. Cardiovascular Interventions|May 26, 2026
REPLY: Bleeding in Infarct-Related Cardiogenic Shock: The Need for an Integrated Hemocompatibility AssessmentRikke Sørensen, Rasmus P Beske, Jacob E Møller, et al.
Pageof 26